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Lymphoma  and  myeloma:  Multiple  imaging
modalities  at  the  heart  of  care
In  order  for  the  haematologist  to  manage  patients  with
lymphoma  and  myeloma,  consultation  is  needed  with  the
after  chemotherapy  and/or  radiotherapy,  together  with  a
negative  PET  scan  result,  indicates  that  there  is  no  resid-
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sradiologist,  specialist  in  nuclear  medicine,  pathologist,  and
radiotherapist:  multimodality  imaging  combining  both  mor-
phologic  and  metabolic  information  is  starting  to  become
an  integral  part  of  diagnosis  and  treatment  decisions,
especially  during  multidisciplinary  meetings,  irrespective
of  disease  stage.  The  purpose  of  this  FMC  brochure  is  to
focus  on  the  role  of  imaging  technicians  in  haematological
malignancies,  from  the  initial  diagnosis  through  to  assessing
response  to  treatment.
Lymphoma
This  diagnosis  is  made  based  on  anatomical  pathology  inves-
tigations  (it  is  essential  to  have  an  optimum  quality  biopsy
specimen  available  from  the  point  when  initial  diagnosis  is
made,  whether  it  is  obtained  surgically  or  under  CT  guid-
ance)  using  frozen  specimens  of  sufﬁcient  size  that  can  be
categorised,  and  this  is  considered  together  with  an  assess-
ment  of  disease  spread  and  the  classiﬁcation  score  taking  in
clinical  information  and  laboratory  studies.  Over  the  last  few
years,  the  emergence  of  the  metabolic  imaging  technique,
FDG-PET  scanning  has  changed  the  way  in  which  the  haema-
tologist  can  manage  lymphoma;  CT  scanning  of  the  chest,
abdomen,  and  pelvis  nonetheless  remains  indispensable,
and  is  routinely  carried  out  as  part  of  the  initial  assessment
and  at  the  end  of  treatment.  According  to  international  rec-
ommendations,  PET  is  indicated  for  an  assessment  of  disease
spread  in  lymphomas  that  show  strong  FDG  uptake,  such  as
diffuse  large  B-cell  lymphoma  (DLBCL)  and  Hodgkin’s  lym-
phoma,  and  it  has  greater  sensitivity  and  speciﬁcity  than
CT.  The  evaluation  of  the  patient’s  response  to  treatment  is
based  on  morphologic  criteria  established  by  Cheson  in  1999,
although  the  IWC  2007  criteria  may  replace  these  when
both  morphologic  and  metabolic  response  are  combined.
The  ﬁnding  of  residual  masses  on  computed  tomography
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http://dx.doi.org/10.1016/j.diii.2013.01.015al  disease.  A  positive  PET  ﬁnding  of  a  residual  mass  can  be
haracterised  if  necessary  using  a  CT-guided  biopsy  taken
rom  the  zone  showing  the  greatest  uptake.  While  the  nodal
orm  is  the  most  common  type  of  lymphoma,  it  is  important
o  know  when  to  consider  a  diagnosis  of  extranodal  lym-
homatous  disease,  which  can  affect  any  organ,  and  can  call
nto  question  diagnoses  of  primary  or  secondary  tumours;
he  radiologist  must  provide  the  evidence  by  taking  biopsy
pecimens,  and  an  inappropriate  surgical  intervention  may
hus  be  avoided.  During  consultation  with  the  haematolo-
ist,  the  imaging  technician  must  bear  in  mind  what  is  really
t  issue  with  treatment:  aggressive  lymphomas  are  generally
ighly  sensitive  to  chemotherapy  with  fewer  relapses  later
n,  while  indolent  lymphomas,  which  are  also  often  sensitive
o  chemotherapy,  tend  to  relapse.  Interim  PET  assessments
ave  now  been  proven  to  have  prognostic  value  in  LDBCL  and
odgkin’s  lymphoma,  but  their  impact  on  early  changes  in
reatment  remains  to  be  deﬁned  in  clinical  trials:  standard-
sation  between  functional  and  metabolic  imaging  would
eem  to  be  essential  for  these  treatment  approaches  to  be
alidated.
yeloma
his  is  a  haematological  malignancy  that  is  caused  by  the
roliferation  of  malignant  plasma  cells  within  the  bone  mar-
ow  that  secrete  monoclonal  immunoglobulin  presenting  in
he  blood  and/or  urine,  and  it  is  often  discovered  due  to
ytic  bone  lesions  that  can  be  detected  on  plain  radiography
‘‘punched-out’’  lesions,  compression  fractures,  etc.).  CT
canning  is  better  than  standard  radiography  because  it  can
etect  small  osetolytic  lesions,  guide  biopsies  in  order  to
btain  histological  evidence,  and  assess  the  risk  of  fracture
r  instability,  but  like  conventional  radiography  it  remains
imited  in  terms  of  demonstrating  response  to  treatment.
 on behalf of the Éditions françaises de radiologie.
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RI  is  more  sensitive  than  conventional  imaging,  especially
hen  assessing  the  axial  skeleton,  enabling  a  distinction
o  be  made  between  normal  and  invaded  bone  marrow:
t  visualises  extramedullary  masses  very  clearly  and  is  an
ndispensable  modality  when  there  is  a  suspicion  of  spinal
ord  compression  or  nerve  compression.  But  assessing  the
atient’s  response  to  treatment  remains  difﬁcult  given  that
esions  can  exist  for  a  long  time  in  a  patient  who  has  made  an
xcellent  response  to  treatment.  Once  again,  as  several  clin-
cal  trials  have  shown,  metabolic  imaging  is  gradually  taking
he  lead  with  its  greater  sensitivity  than  MRI,  whether  it  is
sed  at  the  time  of  the  initial  diagnosis  or  for  the  assess-
ent  of  treatment  response.  It  has  been  demonstrated  that
 negative  result  on  PET-FDG  allows  for  a  prediction  to  be
ade  of  greater  event-free  survival  and  longer  overall  sur-
ival.  A  French  programme  to  support  expensive  innovative
echniques  (STIC)  is  underway  to  prospectively  and  compar-
tively  assess  MRI  and  PET  used  in  an  intensive  treatment
rogramme.  In  myeloma,  the  debate  has  therefore  begun
nto  deﬁning  the  respective  roles  of  conventional  imaging
nd  PET  scanning.  In  the  same  way  as  for  lymphoma,  we
ope  that  in  the  future  these  two  imaging  techniques  will
e  complementary,  carried  out  together  in  real  time  with
he  advent  of  hybrid  MRI/PET  systems,  leading  to  greater
edical  and  economic  efﬁciency.
nfectious chest complications in
aematological malignancies
round  50%  of  patients  with  a  haematological  malignancy
ill  present  a  pulmonary  infection  during  their  man-
gement,  with  high  morbidity  requiring  broad-spectrum
nti-infective  treatments.  Multidisciplinary  consultation  is
nce  again  essential  and  authors  agree  unanimously  on  the
rucial  role  of  the  CT  scan  both  for  the  initial  diagnosis  and
he  monitoring  of  these  patients:  a  CT  scan  carried  out  in
ood  time  is  often  the  key  to  diagnosis  and  decision-makingContinuing  education  program:  Editorial
s it  can  indicate  suitability  for  a  CT-guided  endoscopy
arried  out  by  a  pulmonologist  or  biopsy  carried  out  by  a
adiologist.  Although  a  formal  diagnosis  of  aetiology  remains
mpossible  based  only  on  the  assessment  of  a  chest  CT  scan,
ndings  can  sometimes  be  highly  suggestive  of  a  diagnosis
f  aspergillosis,  pneumocystosis,  or  Haemophilus  inﬂuenzae
ronchiolitis.  CT  therefore  allows  possible  diagnoses  to  be
ut  forward  and  prioritised  to  then  be  correlated  with  clin-
cal  information  and  laboratory  study  results:  this  is  the  key
ole  of  the  radiologist  in  multidisciplinary  discussions  with
aematologists  or  pulmonologists.
The  authors  of  the  different  chapters  of  this  FMC
rochure  have  attempted  to  deﬁne  the  issues  at  stake  in
erms  of  diagnosis  and  treatment  as  they  must  be  under-
tood  by  an  imaging  technician  during  the  often-difﬁcult
ultidisciplinary  decision-making  process  in  haematologi-
al  malignancies.  It  is  also  an  opportunity  to  emphasise  the
omplementary  nature  of  radiology  and  nuclear  medicine  in
his  ﬁeld  and  the  need  to  increase  cooperation  in  oncologic
maging.  This  is  the  real  challenge  of  the  development  of
maging.  We  offer  them  our  thanks  and  hope  that  you  will
ot  hesitate  to  consult  this  brochure  as  necessary.
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